“BeyondSpring announced that Pliabulin has met its primary endpoint in the P2 portion of its global Phase 2/3 clinical trial (Study 105) for the prevention of CIN with docetaxel. In addition, the company announced that a p value of < 0.0001 from its ongoing Phase 3 NSCLC clinical trial (Study 103) was achieved from 138 patients on a secondary endpoint of grade 4 neutropenia, which demonstrates Plinabulin’s ability to reduce docetaxel CIN. Interim anti-cancer efficacy data from Study 103 is expected in mid-2018.",” the firm’s analyst commented.
Other equities research analysts have also recently issued research reports about the stock. HC Wainwright restated a buy rating and set a $50.00 target price on shares of Beyondspring in a research note on Monday, August 21st. Seaport Global Securities started coverage on shares of Beyondspring in a research note on Tuesday, December 5th. They set a buy rating and a $56.00 target price on the stock. Finally, Zacks Investment Research cut shares of Beyondspring from a hold rating to a sell rating in a research report on Monday, November 13th. One research analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. The company presently has a consensus rating of Buy and an average target price of $54.50.
Beyondspring (NASDAQ BYSI) traded up $3.31 during midday trading on Thursday, reaching $32.42. 3,919 shares of the company’s stock were exchanged, compared to its average volume of 5,414. Beyondspring has a 12 month low of $16.55 and a 12 month high of $48.49.
Beyondspring (NASDAQ:BYSI) last released its earnings results on Thursday, November 9th. The company reported ($0.68) EPS for the quarter, topping analysts’ consensus estimates of ($0.69) by $0.01. equities analysts forecast that Beyondspring will post -4.43 earnings per share for the current year.
A hedge fund recently bought a new stake in Beyondspring stock. Tanaka Capital Management Inc. bought a new stake in Beyondspring Inc (NASDAQ:BYSI) in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 21,322 shares of the company’s stock, valued at approximately $914,000. Beyondspring makes up about 2.1% of Tanaka Capital Management Inc.’s investment portfolio, making the stock its 16th biggest holding. Tanaka Capital Management Inc. owned 0.10% of Beyondspring at the end of the most recent quarter. Institutional investors and hedge funds own 1.22% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This piece was first reported by Transcript Daily and is the property of of Transcript Daily. If you are viewing this piece on another publication, it was stolen and reposted in violation of U.S. and international copyright legislation. The correct version of this piece can be viewed at https://transcriptdaily.com/2017/12/16/beyondspring-bysi-given-a-52-00-price-target-by-maxim-group-analysts.html.
BeyondSpring Inc is a global clinical-stage biopharmaceutical company. The Company is focused on the development of cancer therapies. The Company is engaged in advancing its lead product, Plinabulin, into a Phase II/III clinical trial for the reduction of docetaxel chemotherapy-induced severe, grade 4 neutropenia; a Phase II/III clinical trial for the prevention of non-docetaxel chemotherapy-induced severe, grade 4 neutropenia, and a Phase III clinical trial as an anticancer agent in combination with docetaxel in advanced non-small cell lung cancer (NSCLC).
Receive News & Ratings for Beyondspring Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beyondspring and related companies with MarketBeat.com's FREE daily email newsletter.